ID
22170
Description
This is an open-label extension to study 49653/461, to assess the long-term safety of rosiglitazone (extended release tablets) in subjects with mild to moderate Alzheimer's Disease. GSK Source & Descriptions: https://clinicaltrials.gov/ct2/show/NCT00381238?term=NCT00381238&rank=1
Link
https://clinicaltrials.gov/ct2/show/NCT00381238?term=NCT00381238&rank=1
Keywords
Versions (2)
- 5/9/17 5/9/17 -
- 5/22/17 5/22/17 -
Uploaded on
May 22, 2017
DOI
To request one please log in.
License
Creative Commons BY-NC 3.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Investigational Product Visit 1 (Week 0) Open-Label Extension Assessing Long-Term Safety Of Rosiglitazone In Subjects With Mild To Moderate Alzheimer's Disease NCT00381238
Laboratory Data Open-Label Extension Assessing Long-Term Safety Of Rosiglitazone In Subjects With Mild To Moderate Alzheimer's Disease NCT00381238
Description
Compliance
Alias
- UMLS CUI-1
- C1321605
Description
Treatment Confirmation
Alias
- UMLS CUI-1
- C0750484
- UMLS CUI-2
- C0087111
Similar models
Laboratory Data Open-Label Extension Assessing Long-Term Safety Of Rosiglitazone In Subjects With Mild To Moderate Alzheimer's Disease NCT00381238
C0808070 (UMLS CUI [1,2])
C0806020 (UMLS CUI [1,2])
C0039225 (UMLS CUI [1,2])
C0039225 (UMLS CUI [1,2])
C0087111 (UMLS CUI-2)
C2348235 (UMLS CUI [1,2])